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Synopsis 27 
Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir, has oral bioavailability 28 
(25%) limited by intestinal transport (p-glycoprotein), and intestinal degradation 29 
(carboxylesterase). However, the influence of luminal pancreatic enzymes is not fully 30 
understood. Physiologically-based pharmacokinetic (PBPK) modelling has utility for 31 
estimating drug exposure from in vitro data. This study aimed to develop a PBPK 32 
model that included luminal enzyme activity to inform dose reduction strategies. TDF 33 
and TFV stability in porcine pancrelipase concentrations was assessed (0, 0.48, 4.8, 34 
48 and 480U/mL lipase; 1mM TDF; 37˚C; 0 – 30 min). Samples were analyzed using 35 
mass spectrometry. TDF stability and permeation data allowed calculation of 36 
absorption rates within a human PBPK model to predict plasma exposure following 37 
six days of once-daily 300 mg TDF dose. Regional absorption of drug was simulated 38 
across gut segments. TDF was degraded by pancrelipase (half-life 0.07 and 0.62 39 
hours using 480 and 48 U/mL, respectively). Previous literature Cmax (335 ng/mL), 40 
Tmax (2.4 hr) and AUC0-24hr (3045 ng.hr/mL) and C24hr (48.3 ng/mL) were all within 41 
0.5-fold difference of the simulated Cmax (238 ng/mL), Tmax (3 hr) and AUC0-24hr (3036 42 
ng.hr/mL) and C24hr (42.7 ng/mL). Simulated TDF absorption was higher in 43 
duodenum and jejunum than ileum (p<0.05). These data support that TDF 44 
absorption is limited by the action of intestinal lipases. Results suggest that 45 
bioavailability may be improved by protection of drug from intestinal transporters and 46 
enzymes, for example by co-administration of enzyme inhibiting agents or 47 
nanoformulation strategies.  48 
  
1. Introduction 49 
Human immunodeficiency virus (HIV) is currently an incurable disease which 50 
constitutes a serious global health crisis. Oral antiretroviral therapy is the mainstay of 51 
current therapy and involves coadminstration of drugs targeting multiple viral targets. 52 
Both drug-related adverse reactions and drug resistance have led to the 53 
development of newer antiretroviral drugs and drug classes. However, the cost and 54 
dosing schedule of treatments are a significant concern in low- and middle-income 55 
countires (L&MICs). Several effective antiretroviral drugs are now manufactured as 56 
generics and are marketed  with significant cost savings to payers (1, 2).  57 
 58 
Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), is a cornerstone of 59 
first-line treatment in low-income and middle-income countries. TDF is a nucleotide-60 
reverse transcriptase inhibitor (NtRTI), which prevents viral DNA chain lengthening 61 
and replication (3) (Figure 1). During preclinical development, TFV demonstrated low 62 
oral bioavailability (around 13%) (4) and TDF was developed to improve this by 63 
removing charged regions and increasing lipophilicity. However, the oral 64 
bioavailability of TDF was only moderately improved and is estimated at around 25% 65 
in fasted subjects (5, 6). Substantially improving the bioavailability of TDF would 66 
provide significant cost-saving in L&MICs. In order to achieve this, it is important to 67 
understand the causes of low TDF bioavailability and to formulate potential targeting 68 
strategies. 69 
 70 
Using Caco-2 monolayers as a model for the intestinal epitheial surface, the drug 71 
efflux transporter ABCB1 has been shown to readily transport TDF (7). As ABCB1 is 72 
involved in the elimination of substrates from the enterocytes of the intestine back 73 
  
into the luminal space, it is hypothesised that inhibitors of ABCB1 may improve TDF 74 
oral absorption. However, this ABCB1 inhibitory effect was not observed in situ using 75 
perfusion studies in rats (8). The significance of this finding is not clear due to the 76 
significantly faster TDF degradation in rat duodenal and ileal enterocytes compared 77 
to corresponding human enterocytes (9). 78 
 79 
Previous studies have investigated the impact of co-administered HIV protease 80 
inhibitors on TFV pharmacokinetics (7). Ritonavir-boosted protease inhibitors 81 
atazanavir, lopinavir, darunavir and saquinavir all showed a modest increase in TFV 82 
exposure when co-administered with TDF. Protease inhibitors show varying degrees 83 
of ABCB1 inhibition in vitro. Therefore, the same study also investigated the impact 84 
of these drugs on ABCB1-mediated transport of TDF. Darunavir, which in patients 85 
led to a 22% increase in TFV exposure, had no impact on TDF transport in vitro. In 86 
the case of the interactions observed with protease inhibitors and possibly other 87 
drugs, additional bioavailability-related mechanisms are likely to be involved 88 
alongside ABCB1. 89 
 90 
TDF is rapidly metabolised to TFV in the presence of rat intestinal microsomes (8). It 91 
was hypothesised that carboxylesterase was responsible for this metabolism, and 92 
further investigations showed improved drug stability in the presence of certain 93 
natural fruit extracts and pharmacological esters. Protease inhibitors have shown 94 
varying degrees of carboxylesterase inhibition, and this enzyme may therefore be 95 
involved in interactions between TDF and these drugs. 96 
 97 
  
Pancreatic enzymes, including lipase, amylase and trypsin, are released into the 98 
duodenum and are involved in the breakdown of ingested food in preparation for 99 
nutrient absorption. Pancreatic lipase is known to hydrolyse ester bonds (10), but the 100 
ability of lipase to metabolise TDF by ester-linked chain removal has not been 101 
previously investigated.  102 
 103 
The initial aim of this study was to determine in vitro the extent of TDF metabolism 104 
by pancreatic lipase. This data was combined with previous information on TDF 105 
ABCB1-mediated transport and carboxylesterase metabolism to create a PBPK 106 
model with informed absorption mechanisms involving all these processes. The 107 
model generated was then used to estimate the relative importance of these factors 108 
in TDF absorption, providing a platform to postulate possible dose reduction 109 
strategies.  110 
 111 
  
2. Results 112 
2.1 Stability of TDF in pancrelipase 113 
The breakdown of TDF was determined at various concentrations of lipase. The half-114 
life of TDF was determined as 4.0 minutes in 480 U/mL lipase and 37.5 minutes in 115 
48 U/mL lipase. TDF was stable in 4.8 U/mL lipase and below, therefore half-life was 116 
not determined at these concentrations. Data was used to generate an equation, 117 
given below, relating lipase concentration to TDF stability, which was used to inform 118 
the PBPK model. 119 
 120 
TDF1/2 = -0.0013 * [Lipase] + 0.6863 121 
 122 
Where TDF1/2 is the half life of TDF (hr); [Lipase] is the concentration of lipase in the 123 
intestine (units/mL). To confirm the role of lipase in TDF degradation, selective 124 
inhibition of pancreatic enzymes were performed and the influence on TDF half life 125 
was evauated. Co-incubation of TDF with lipase inhibitor orlistat resulted in a 33% 126 
increase in TDF half life (16.0 min) compared to inhibitor-free incubation (12.0 min, p 127 
= 0.02), whereas no alteration in TDF half life was observed with co-incubation with 128 
amylase inhibitor acarbose (12.6 min, p = 0.66) or trypsin inhibitor type 1-S from 129 
glycine max (soybean) (12.7 min, p = 0.23). 130 
 131 
2.2 Model verification 132 
The 300 mg once-daily steady state TFV pharmacokinetic study by Barditch-Crovo 133 
et al showed variability in median pharmacokinetic parameters Cmax, Tmax, AUC0-24hr 134 
  
assessed between days 8, 15 and 35 days of the study (6). Therefore, a mean and 135 
standard deviation between these assessment days was calculated and used for 136 
comparison with simulated data. The clinical Cmax (335 ng mL
-1), Tmax (2.4 hr) and 137 
AUC0-24hr (3045 ng.hr mL
-1) were all within 0.5-fold difference of the simulated Cmax 138 
(238 ng mL-1, 0.41-fold higher), Tmax (3 hr, 0.2-fold lower) and AUC0-24hr (3036 ng.hr 139 
mL-1, 0-fold difference). The observed median TFV C24hr following seven days of 140 
once-daily 300 mg oral dosing was 48.3 ng mL-1, which was within the acceptable 141 
range of the median simulated TDF C24hr of 42.7 ng mL
-1 (Figure 2A). The terminal 142 
plasma half life of TFV was determined as 11.7 hours and 8.5 hours from the median 143 
clinical and simulated pharmacokinetic data, respectively, following seven days of 144 
300 mg once-daily oral dosing. The simulated mean bioavailability of 300 mg of 145 
orally dosed TDF was 21.2 ± 3.3 % (range 13.1-27.6 %). This estimation of oral 146 
bioavailability slightly underpredicted the 25% value estimated to be bioavailable 147 
from clinical studies. To validate the robustness of the model further, simulations 148 
were performed as described above but using alternative TDF oral dose sizes (75 149 
mg, 150 mg and 600 mg) and plasma concentration curves compared with previous 150 
clinical data (6). For the 75 mg TDF dose, the clinical Cmax (53 ng mL
-1) and Tmax (2.5 151 
hr) were within 0.5-fold difference of the simulated Cmax (51 ng mL
-1, 0.03-fold higher) 152 
and Tmax (3 hr, 0.2-fold lower) (Figure 2B). The AUC0-24hr and C24hr for the 75 mg 153 
dose could not be determined from the clinical data as TFV was undetectable at the 154 
0 and 24 hour time points on the plasma concentration curve. Therefore, clinical 155 
AUC1-12hr (480 ng.hr mL
-1) and C12hr (34 ng mL
-1) were compared to simulated AUC1-156 
12hr (488 ng.hr mL
-1, 0.02-fold lower) and C12hr (28 ng mL
-1, 0.21-fold higher) (Figure 157 
2B). For the 150 mg TDF dose, the clinical Cmax (135 ng mL
-1), Tmax (2.5 hr), AUC0-158 
24hr (1581 ng.hr mL
-1) and C24hr (29 ng mL
-1) were all within 0.5-fold difference of the 159 
  
simulated Cmax (112 ng mL
-1, 0.21-fold higher), Tmax (2 hr, 0.25-fold higher), AUC0-24hr 160 
(1581 ng.hr mL-1, 0-fold difference) and C24hr (23 ng mL
-1, 0.26-fold higher) (Figure 161 
2C). For the 600 mg TDF dose, the clinical Cmax (618 ng mL
-1), Tmax (2.5 hr), AUC0-162 
24hr (6166 ng.hr mL
-1) and C24hr (111 ng mL
-1) were all within 0.5-fold difference of the 163 
simulated Cmax (574 ng mL
-1, 0.08-fold higher), Tmax (2 hr, 0.25-fold higher), AUC0-24hr 164 
(7547 ng.hr mL-1, 0.18-fold lower) and C24hr 106 ng mL
-1, 0.05-fold higher) (Figure 165 
2D). 166 
 167 
2.3 Simulations of TDF and TFV fractional absorption  168 
The regional intestinal absorption of TDF and TFV was simulated over 24 hours in 169 
100 virtual subjects following a single 300 mg oral dose of TDF (Figure 3). The 170 
majority of drug entering the systemic circulation was predicted to be accounted for 171 
by absorption of TDF directly, predominantly via the duodenum (11.7 mg) and 172 
section 1 of the jejunum (11.6 mg). Compared to absorption of TDF, overall 173 
absorption of TFV was predicted to be minor and varied from 0.15 mg in the 174 
duodenum to 1.19 mg in section 2 of the jejunum.  175 
 176 
2.4 Simulations of tenofovir plasma concentrations following inhibition of 177 
intestinal ABCB1, CES and luminal lipase 178 
Data was found to be non-normally distributed so a Mann Whitney U test was used 179 
to determine significance. The median tenofovir AUC0-24hr (5
th-95th centile) of the 180 
control group (3036 (1752-4762) ng.hr mL-1) was significantly less than other groups 181 
following inhibition of ABCB1 (4480 (2538-7228) ng.hr mL-1), p<0.01), ABCB1 + 182 
  
carboxylesterase (6018 (3514-10976) ng.hr mL-1), p<0.01), lipase (12873 (9020-183 
20827) ng.hr mL-1), p<0.01), ABCB1 + lipase (17322 (12752-26226) ng.hr mL-1), 184 
p<0.01), and ABCB1 + carboxylesterase + lipase (19250 (14215-29208) ng.hr mL-1), 185 
p<0.01) (Table 2). 186 
 187 
2.5 Simulations of dose reduction strategies  188 
Further simulations were performed where TDF dose was reduced in groups with 189 
inhibited factors, with the aim of achieving a similar (within 10% difference) median 190 
tenofovir AUC0-24hr as was observed in the control group. Comparable tenofovir 191 
exposure was observed in all simulated groups following specific dose reductions in 192 
each case (Table 3). The median AUC0-24hr (5
th-95th centile) following inhibition of 193 
ABCB1 (200 mg dose, 2897 (1678-4603) ng.hr mL-1), ABCB1 + carboxylesterase 194 
(150 mg dose, 3002 (1900-4536) ng.hr mL-1), lipase (90 mg dose, 3337 (2245-5341) 195 
ng.hr mL-1), ABCB1 + lipase (60 mg dose, 3279 (2366-4950) ng.hr mL-1), and 196 
ABCB1 + carboxylesterase + lipase (50 mg dose, 3133 (2286-4751) ng.hr mL-1) 197 
were all within 10% difference of the control group (3036 (1752-4762) ng.hr mL-1). 198 
  199 
  
3. Discussion 200 
In this study we have established that TDF is unstable in the presence of 201 
physiologically relevant concentrations of pancrelipase. The most likely mechanism 202 
of this degradation is ester bond cleavage that first results in the TFV monoester and 203 
finally in TFV. As this process occurs in the luminal fluid prior to drug absorption, it is 204 
hypothesised that luminal lipase activity influences TDF bioavailability in humans. To 205 
investigate this, the impact of luminal lipase was included in the PBPK model to 206 
estimate TFV plasma concentrations. Simulations suggest that the included factors 207 
contribute to the TFV exposure seen in subjects, with luminal lipase having a 208 
significant impact. In addition to results generated in this study, there is supporting 209 
evidence that lipase may be a relevant factor in determining TFV bioavailability. 210 
Protease inhibitors are able to inhibit lipase activity in vitro (11) and this process may 211 
be involved in the interactions seen between TDF and these drugs (possibly in 212 
addition to its known inhibition of transporters). Additionally, TDF exposure was 213 
increased 40% in human subjects when taken with a high-fat meal whereas no 214 
comparable effect was seen with a low-fat meal (3). Although it is common to see 215 
improved biovavailability of highly lipophilic and insoluble drugs when taken with a 216 
fatty meal, TDF is reasonably soluble in intestinal fluid. Alternatively, it can be 217 
hypothesised that the increased fat in the intestinal fluid limits availability of lipase 218 
active sites for TDF metabolism. However, this competition has not been assessed 219 
and requires further empirical confirmation. 220 
 221 
The authors have successfully employed PBPK modelling to include a variety of 222 
factors that influence TDF absorption. However, due to existing knowledge gaps and 223 
  
the complexities of biological processes involved in TFV pharmacokinetics, there are 224 
limitations to this approach and it is important that these limitations are addressed. 225 
The simulations were undertaken assuming a population of fasted subjects, and the 226 
influence of ingested food and fats was not considered. This was due to incomplete 227 
information on the effects of food and fats on intestinal lipase activity and the 228 
influence of this on TDF stability. It was assumed that lipase was only active in the 229 
small intestine compartments and that the level of activity did not vary between these 230 
compartments in individual subjects. Per amount of enzyme, the activity level of the 231 
lipase was assumed to be similar in both an in vitro and in vivo environment, and in 232 
the in vitro experiments the authors used FaSSIF to replicate the environment in the 233 
fasted-state luminal fluid. Additionally, the use of porcine pancrelipase was chosen 234 
by the authors due to the well characterised enzymatic activity of the product, where 235 
precise units of all enzymes (ie activity of lipase, amylase and trypsin) per weight of 236 
substance was known, whereas human pancreatic fluids available to the authors did 237 
not provide the required information needed for utilisation in the PBPK model. The 238 
distribution levels and activity levels of carboxylesterase protein in different sections 239 
of the intestine is unknown; therefore it was assumed that the Caco-2 intestinal 240 
model was a suitable surrogate system. 241 
 242 
Reformulation of TDF offers a strategy to improve bioavailability. There are cases 243 
where multiple formulations of an antiretroviral are available, often for specific 244 
scenarios such as in paediatric treatment. Comparison studies have shown that 245 
formulation composition can significantly influence antiretroviral pharmacokinetics 246 
(1). Extended release formulations have proven beneficial in many diseases, and 247 
  
may have the potential to protect TDF from luminal enzymes. Inhibition of ABCB1 or 248 
carboxylesterase alone is unlikely to have a dramatic effect on TFV bioavailability, 249 
but a more holistic approach to inhibit multiple proteins (including lipase) may be 250 
more successful. This is somewhat supported by the modest increase in TFV 251 
exposure observed on coadminstration with boosted protease inhibitors, and a more 252 
target-driven approach may achieve greater increases. Emerging nanotechnologies 253 
may also provide bespoke opportunities to encapsulate and protect TDF from 254 
degradation until absorption is complete (12). 255 
 256 
4. Materials and Methods 257 
4.1 Determination of TDF stability in pancrelipase 258 
The stability of 1 mM TDF was assessed in triplicate in a range of lipase 259 
concentrations (0, 0.48, 4.8, 48 and 480 U/mL) using porcine pancrelipase. The 260 
medium used to perform experiments was Fasted Simulated Small Intestinal Fluid 261 
(FaSSIF; 3 mM sodium taurocholate, 0.2 mM lecithin, 34.8 mM sodium hydroxide, 262 
68.62 mM sodium chloride, maleic acid 19.12 mM, deionized water 1L, hydrogen 263 
chloride added dropwise to achieve pH 6.5) and TDF concentrations were assessed 264 
at 0, 5, 10, 15, 20 and 30 minutes. Parallel experiements were performed to identify 265 
the specific enzymes involved in TDF degradation, where saturating concentrations 266 
of inhibitors of lipase (100 µg/mL orlistat), amylase (1 mg/mL acarbose) and trypsin 267 
(1 mg/mL Type 1-S trypsin inhibitor from soybean) (13) were co-incubated with 20 268 
µg/mL TDF and alterations in TDF half life were determined in the presence of a mix 269 
of porcine pancreatic enzymes (100 U/mL lipase, 540 U/mL amylase and 340 U/mL 270 
trypsin). All experiements were performed at 37ºC and samples were processed and 271 
  
analysed at Scynexis (Durham, NC, USA) using LC-MS/MS. The column used was a 272 
Synergi Polar RP 2.0x150mm 4um (Phenomenex) kept at 60˚C, mobile phase A 273 
consisted of 96%/3%/1% water/acetonitrile/acetic acid and mobile phase B consisted 274 
of 3%/96%/1% water/acetonitrile/acetic acid. Flow rate was 600 µL/min and 275 
consisted of 100% A between 0 to 1 minutes, 2% A 98% B at 2 minutes, 2% A 98% 276 
B at 3 minutes, 100% A at 3.1 minutes, 100% A at 4 minutes. TDF was detected in 277 
positive mode, Q1 mass was 520.1 and Q3 mass was 270 using collision energy 34. 278 
Labetalol was used as internal standard.  279 
 280 
4.2 Model construction  281 
The PBPK model was created using SimBiology version 3.3, a product of Matlab 282 
v.8.2 (MathWorks, Natick, MA, USA, 2013). The aim of the PBPK model was to 283 
simulate the steady-state pharmacokinetics of TFV in humans following six days of 284 
once-daily 300 mg TDF administration. In particular, the aspects potentially relevant 285 
to TDF absorption (solubility, lipase activity, carboxylesterase activity, ABCB1 286 
activity) were included to simulate the relative importance of each factor. 287 
 288 
4.3 System parameters 289 
The basic structure of the PBPK model is based on previously published model 290 
created by the authors (14). Demographic factors of virtual male subjects between 291 
the ages of 18 and 60 (height, weight, body mass index, body surface area) were 292 
taken from published literature and used in allometric equations to calculate 293 
individual organ volumes (15). The volume and rate of blood circulation in each 294 
  
simulated subject was calculated as previously described (16). The model was 295 
created with the following assumptions: 1) tissue compartments were treated as well-296 
stirred compartments with instant distribution of drug; 2) drug was not absorbed from 297 
the stomach compartment; 3) the rate of drug absorption from the caecum and colon 298 
was reduced to 10-fold less than would be observed in the small intestine under the 299 
same conditions; 3) the model is blood-flow-limited. The physiological factors 300 
relevant for drug absorption in the intestinal compartments are based on the 301 
Advanced Compartmental Absorption and Transit (ACAT) model and are given in 302 
Table 1 (17).  303 
 304 
4.4 Drug parameters 305 
4.4.1 Solubility of TDF in the luminal fluid 306 
In order to account for potential solubility-induced absorption limitations, the solubility 307 
of TDF was measured by Corealis Pharma (Quebec, Canada) in a physiologically-308 
relevant range of buffered pH solutions. Solubility of TDF was high at 9300, 4800 309 
and 6200 mg/L in buffered solutions of pH 2, 4.5 and 8, respectively. These results 310 
were then used to derive a quadratic equation, given below, to calculate the pH-311 
dependent limitations to TDF luminal solubility (mg/L) in the PBPK model intestinal 312 
compartments. 313 
 314 
TDFs = (366.67 * [IpH]2) – (4183.33 * IpH) + 16200 315 
 316 
  
Where TDFs is the maximum possible solubility of TDF (mg/L); IpH is the pH of the 317 
intestinal segment fluid. 318 
 319 
 Only soluble TDF, which was continually determined throughout simulations in each 320 
intestinal segment, was available for absorption in the PBPK absorption model.  321 
 322 
4.4.2 Stability of TDF in the luminal fluid  323 
Intestinal lipase concentrations were acquired from literature and included in the 324 
small intestine segments of the PBPK model (duodenum, jejunum and ileum) (18). 325 
Each simulated fasted subject was given a physiologically-relevant concentration of 326 
luminal lipase which was randomly assigned within the ranges obtained from 327 
published literature of between 100 and 400 units/mL. Using the in vitro metabolism 328 
data generated in this study, an equation was then developed establishing the 329 
relationship between lipase concentration and drug half life, as given in the results 330 
section. The lipase-dependent rate of elimination was then determined for each 331 
simulated subject and the degraded TDF was assumed to be converted to TFV, 332 
which is either absorbed or passes along and out of the intestine, as detailed below. 333 
 334 
4.4.3 Absorption of TDF and TFV 335 
TDF permeation through a Caco-2 monolayer has been previously investigated and 336 
the apparent permeability (Papp) was found to be drug-concentration-dependent (7). 337 
The authors hypothesised that this was the result of active transport saturation 338 
  
(specifically saturation of ABCB1) when higher TDF concentrations were added to 339 
the receiver compartment. To inform the current model of this scenario, this 340 
relationship between TDF concentrations and Papp was continuously re-determined 341 
in each intestinal segment using a polynomial equation, given below, derived from a 342 
previous study (7). 343 
 344 
TDFPapp = -1.9*10
-26 * [TDFconc]
6 + 3.3*10-22 * [TDFconc]
5 – 2.2*10-18 * [TDFconc]
4 345 
+ 7.5*10-15 * [TDFconc]
3 – 1.3*10-11 * [TDFconc]
2 + 1.1*10-8 * [TDFconc] + 1.6*10
-7 346 
 347 
Where TDFPapp is the estimated TDF Papp value at a specific concentration of TDF; 348 
TDFconc is the concentration of TDF. 349 
  
 350 
Using previously established equations, Papp was used to generate the rate of drug 351 
absorption in the model (19, 20). Intestinal absorption of TFV, the breakdown 352 
product of TDF occurring via luminal lipase, was included. The rate of intestinal TFV 353 
absorption was determined by scaling the Papp value of 0.41 cm x 10
-6 s-1 determined 354 
previously in MDCK monolayers (21) (22). 355 
 356 
4.4.4 Distribution of TFV 357 
The volume of distribution of TFV was simulated considering the volume of 358 
distribution of 0.813 L/kg described in population pharmacokinetic studies (23) and 359 
tissue distribution was determined using previously published equations (24, 25). 360 
 361 
4.4.5 Clearance of TFV 362 
TFV is predominantly eliminated from the body unchanged via the kidneys. In order 363 
to account for this loss, clearance of TFV was included in the model. The multiple 364 
physiological factors involved in the elimination of TFV, such as the effect of drug 365 
transporters and tubular reabsorption, have not been fully characterised, making a 366 
mechanistic prediction of TFV renal elimination difficult. Therefore, a TFV total 367 
clearance rate of 0.066 L/hr/kg was derived from a previous population 368 
pharmacokinetic study and was included in our model (6). 369 
 370 
  
4.5 Model verification 371 
To verify the model, pharmacokinetic data from simulations were compared to 372 
clinical data. Following six days of once-daily dosing of 300 mg TDF in 100 simulated 373 
subjects, median TFV Cmax, Tmax, AUC0-24hr and C24hr were calculated and contrasted 374 
to steady state pharmacokinetics observed in real subjects, taken from a 375 
randomized, double-blind, placebo-controlled, escalating-dose study of four doses 376 
(75, 150, 300, and 600 mg given once daily) with between eight and nine subjects in 377 
each group (6). Additionally, the terminal plasma half life of TDF was estimates from 378 
simulated concentration plots and compared to half life generated from clinical data. 379 
The bioavailability of orally administered TDF is estimated at around 25 % of the total 380 
dose (26) and the bioavailability of 300 mg orally administered TDF was determined 381 
from our simulations (mean ± standard deviation, with minimum and maximum 382 
range) as a comparison to further validate the model. As a pre-determined measure 383 
of success for the model validation, a difference of 0.5-fold or less between clinical 384 
and predicted pharmacokinetic parameters was deemed acceptably accurate (27) 385 
(28). Pharmacokinetic parameters were determined by non-compartmental analysis 386 
using PK Solutions 2.0 (Summit Research Services, UK). 387 
To validate the robustness of the model further, simulations were performed as 388 
described above but using alternative TDF oral dose sizes (75 mg, 150 mg, 600 mg). 389 
Pharmacokinetic parameters (median TFV Cmax, Tmax, AUC0-24hr and C24hr) were 390 
generated from these simulations and were compared to available clinical 391 
pharmacokinetic data where these dose sizes were utilised (6). 392 
 393 
4.6 Assessment of regional absorption of TDF and TFV 394 
  
The regional absorption of TDF and TFV was simulated in 100 virtual subjects 395 
following a single 300 mg oral dose of TDF. Mean absorption amounts (mg) with 396 
standard deviations were determined 24 hours post-dose in duodenum, jejunum 397 
section 1 (j1), jejunum section 2 (j2), ileum section 1 (i1), ileum section 2 (i2), ileum 398 
section 3 (i3), caecum and colon (Table 1).  399 
 400 
4.7 Prediction of TFV pharmacokinetics following inhibition of factors involved 401 
in absorption 402 
In order to determine the influence of intestinal ABCB1, CES and lipase on tenofovir 403 
exposure, each factor was individually (with the exception of CES) and in 404 
combination removed from simulations and the pharmacokinetics of TFV determined 405 
for each combination. In the case where lipase activity in the model was eliminated, 406 
simulations were performed where intestinal TDF1/2 = 0 minutes. In the case where 407 
ABCB1 activity was inhibited, simulations were performed using a TDF Papp value of 408 
3.6 cm x 10-6 s-1 taken from a previous study (7). In the case where ABCB1 and CES 409 
activities in the model were inhibited, simulations were performed using a TDF Papp 410 
value of 9.41 cm x 10-6 s-1 taken from a previous Caco-2 permeation study where 411 
inhibition of ABCB1 and CES activity was achieved using TPGS (ABCB1 inhibitor) 412 
and 1 mM propylparaben (CES inhibitor) (7) (21). In each group, mean tenofovir 413 
Cmax, Tmax, AUC0-24hr and C24hr were calculated following six days of once-daily 414 
dosing of 300mg TDF in 100 simulated subjects.  415 
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 506 
Tables 507 
Table 1. Physiological factors relevant for simulating the oral absorption of TFV 508 
disoproxil and TFV in the PBPK model. 509 
Segment  pH 
Volume 
(mL) 
Radius 
(cm) 
Transit 
time (hr) 
Absorption 
scaling 
Stomach 1.3 46.56 N/A 0.25 x 0 
Duodenum 6 41.56 1.53 0.26 x 1 
Jejunum 1 6.2 154.2 1.45 0.93 x 1 
Jejunum 2 6.4 122.3 1.29 0.74 x 1 
Ileum 1 6.6 94.29 1.13 0.58 x 1 
Ileum 2 6.9 70.53 0.98 0.42 x 1 
Ileum 3 7.4 49.83 0.82 0.29 x 1 
Caecum 6.4 47.49 3.39 4.19 x 1 
Colon 6.8 50.33 2.41 12.57 x 0.1 
  
 510 
 511 
Table 2. Simulated median pharmacokinetic parameters of tenofovir following 512 
inhibition of factors involved in drug absorption of TDF. Parameters were determined 513 
following 6 days once-daily oral dosing of 300 mg TDF in 100 healthy male subjects. 514 
Inhibited factor Cmax (ng mL
-1) Tmax (hr) AUC0-24hr (ng.hr mL
-1) C24hr (ng mL
-1) 
None (control) 238 3 3036 43 
ABCB1 377 2 4480 51 
ABCB1 + CES 538 2 6018 68 
Lipase 1013 3 12873 199 
ABCB1 + lipase 1409 3 17322 235 
ABCB1 + CES + lipase 1642 3 19250 228 
 515 
Table 3. Dose reduction strategies following inhibition of factors involved in drug 516 
absorption of TDF. Parameters were determined following 6 days once-daily oral 517 
dosing of TDF in 100 healthy male subjects. 518 
Inhibited factor Dose size (mg) AUC0-24hr (ng.hr mL
-1) % difference from 
control 
None (control) 300 3036 n/a 
ABCB1 200 2897 -5% 
ABCB1 + CES 150 3002 -1% 
Lipase 90 3337 +10% 
ABCB1 + lipase 60 3279 +8% 
ABCB1 + CES + lipase 50 3133 +3% 
 519 
Figure legends 520 
 521 
Figure 1. The process of converting the prodrug TDF to TFV and ultimately to the 522 
active substance TFV diphosphate. 523 
  
 524 
Figure 2. Validation of the physiologically based pharmacokinetic model strategy 525 
against clinical data of TDF once-daily, day 7 profiles for dose size of 300 mg (Figure 526 
2A), 75 mg (Figure 2B), 150 mg (Figure 2C) and 600 mg (Figure 2D) (6). 527 
 528 
Figure 3. The amount of TDF and tenfovir absorbed via each intestinal segment 529 
following a single 300 mg oral dose of TDF (mg ± SD, 24 hours post-dose). J1 = 530 
jejunum first section; J2 = jejunum section 2; I1 = ileum section 1; I2 = ileum section 531 
2; I3 = ileum section 3. 532 
 533 
 534 
